Polity & Governance
Bombay High Court criticizes food safety body for halting Cadila Pharmaceuticals drug sales
The development
What happened
The Bombay High Court on August 11, 2026, sharply rebuked the Food Safety and Standards Authority of India (FSSAI) for suspending the sale of drugs manufactured by Cadila Pharmaceuticals, calling the action an exercise of power without justification. The court’s remarks came during a hearing on a petition filed by Cadila Pharmaceuticals challenging FSSAI’s decision.
At a glance
Key facts
The Bombay High Court heard a petition from Cadila Pharmaceuticals challenging the FSSAI’s decision to halt drug sales.
The court described the FSSAI’s action as an attempt to "only display power" without valid grounds.
The hearing took place on August 11, 2026.
The FSSAI’s suspension affected the sale of drugs produced by Cadila Pharmaceuticals.
Background
Context
- FSSAI is the national regulator for food safety and standards in India, including oversight of pharmaceuticals in some cases.
- Cadila Pharmaceuticals is a major Indian pharmaceutical company with a broad drug portfolio.
- Courts occasionally intervene in disputes between regulators and industry players to ensure fair and justified actions.
Significance
Why it matters
- Highlights regulatory oversight concerns in India’s pharmaceutical sector, particularly regarding the authority of FSSAI in drug sales.
- Raises questions about the balance between public health safeguards and industry operations.
- Demonstrates judicial scrutiny of regulatory decisions affecting large pharmaceutical firms.